In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems.

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. Antimicrob Agents Chemother. 2020 Sep 14;: Authors: Karlowsky JA, Hackel MA, Bouchillon SK, Sahm DF Abstract WCK 5222 (cefepime-zidebactam, 2g + 1g, q8h) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined in vitro susceptibility of 1,385 clinical isolates of carbapenem not susceptible Enterobacterales, MDR Pseudomonas aeruginosa (also carbapenem not susceptible), Stenotrophomonas maltophilia, and Burkholderia spp. collected worldwide (49 countries) during 2014-2016 to cefepime-zidebactam (1:1 ratio), ceftazidime-avibactam, imipenem-relebactam, ceftolozane-tazobactam, and colistin using CLSI broth microdilution method. Cefepime-zidebactam inhibited 98.5% of carbapenem not susceptible Enterobacterales (n=1,018) at ≤8 μg/ml (provisional cefepime-zidebactam-susceptible MIC breakpoint). Against the subset of metallo-β-lactamase (MBL)-positive Enterobacterales (n=214), cefepime-zidebactam inhibited 94.9% of isolates at ≤8 μg/ml. Further, it inhibited 99.6% of MDR P. aeruginosa (n=262) isolates at ≤32 μg/ml (proposed cefepime-zidebactam-susceptible pharmacokinetic/pharmacodynamic MIC breakpoint), including all MBL-positive isolates (n=94). Moreover, cefepime-zidebactam was active against the maj...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research